Disseminated tumor cells (DTCs) shed from a primary tumor may lie dormant in distant tissues for long periods of time before they can be activated to form metastases. Recently work in our group has shown that (i) the engraftment of hematopoietic stem cells (HSC) and (ii) prostate cancer (PCa) metastasis to the marrow are dependent on many of the same molecules. In fact, we have recently demonstrated that metastatic PCa directly competes with HSC for occupancy of the niche. We have also developed technology and models that permits isolation of human DTCs from marrow using anti-human leukocyte antigens (HLA). Hypothesis: Molecules that induce HSC dormancy also induce dormancy of metastatic PCa cells and can be used to identify DTCs. The following aims are proposed: (1) Identify the differences between circulating tumor cells (CTCs) and successful DTCs. Sub Hypothesis: Dormant DTCs have different profiles from CTCs and dividing DTCs. We will determine the expression levels of receptors, known to regulate homing, lodging and growth, and gene expression profiling on CTCs and DTCs that will be obtained from our murine xenograft model. Then, these analyses will be repeated with CTCs and DTCs obtained from PCa patients. (2) Identify the specific subtype of DTCs that become dormant. Sub hypotheses: DTCs that become dormant have the capability to eventually form tumors. First, we will determine the frequency of tumorigenic cells in the dormant DTCs by implanting into immunocompromized mice. Next, we will determine the tumorogenic phenotype while determining if these cells also have the colony-forming ability and chemo-resistant ability. Finally, we will determine if we can manipulate dormant state of these cells with GAS6 (See Project 2) or IL-6 (See Project 3). (3) Determine the molecular mechanism that is critical for DTCs to become dormant. Sub hypotheses: The binding to annexin 2 (AnxaZ) is critical for DTCs to become dormant We have demonstrated that Anxa2 expressed by osteoblasts is a crucial molecule for the niche selection of PCa, This suggests that PCa obtain the signals from the niche through the Anxa2/Anxa2r axis. Therefore, we will determine if blocking Anxa2r on PCa prevents becoming dormant. In addition, we have observed that when PCa bind to Anxa2, the expression of Axl, the receptors for GAS6, is enhanced on the PCa. Thus, we will determine signaling pathway that is involved in the effects of Anxa2 on Axl induction. These findings will directly lend support to Project 2 which will determine how endosteal HSC niche regulates tumor dormancy, and Project 3 which focuses on what leads to activation of the dormant cells.

Public Health Relevance

In prostate cancer, tumor dormancy is a key event for a long-term survival of disseminated tumor cells (DTCs) in the distant tissues. Our proposed investigations will focus on fundamental mechanisms how DTCs become dormant in the bone marrow. The new insights derived from our investigations will be relevant to identify the phenotype of DTCs that is uniquely responsible for tumor relapse, and will lead to develop new traget therapies for metastatic tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163124-03
Application #
8567739
Study Section
Special Emphasis Panel (ZCA1-SRLB-3)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
3
Fiscal Year
2013
Total Cost
$152,240
Indirect Cost
$95,970
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705
van der Toom, Emma E; Axelrod, Haley D; de la Rosette, Jean J et al. (2018) Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol :
Valkenburg, Kenneth C; de Groot, Amber E; Pienta, Kenneth J (2018) Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol 15:366-381
Chalfin, Heather J; Glavaris, Stephanie A; Malihi, Paymaneh D et al. (2018) Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol 199:1494-1501
Decker, A M; Taichman, L S; D'Silva, N J et al. (2018) Periodontal Treatment in Cancer Patients: An Interdisciplinary Approach. Curr Oral Health Rep 5:7-12
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Maley, Carlo C; Aktipis, Athena; Graham, Trevor A et al. (2017) Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 17:605-619

Showing the most recent 10 out of 79 publications